1
Blatt Lawrence M, Wenglowsky Steven M, Andrews Steven W, Condroski Kevin R, Jiang Yutong, Kennedy April L, Doherty George A, Josey John A, Stengel Peter J, Woodard Benjamin T, Madduru Machender R: Macrocyclic compounds as inhibitors of viral replication. Intermune, Blatt Lawrence M, Wenglowsky Steven M, Andrews Steven W, Condroski Kevin R, Jiang Yutong, Kennedy April L, Doherty George A, Josey John A, Stengel Peter J, Woodard Benjamin T, Madduru Machender R, MALLON Joseph J, October 13, 2005: WO/2005/095403 (110 worldwide citation)

The embodiments provide macrocylic compounds, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of tre ...


2

3
Blatt Lawrence M, Seiwert Scott, Beigelman Leonid, Kercher Timothy, Kennedy April L, Andrews Steven W: Novel inhibitors of hepatitis c virus replication. Intermune, Array Biopharma, Blatt Lawrence M, Seiwert Scott, Beigelman Leonid, Kercher Timothy, Kennedy April L, Andrews Steven W, MALLON Joseph J, January 10, 2008: WO/2008/005511 (58 worldwide citation)

The embodiments provide compounds of the general Formula (I), as well as compositions, including pharmaceutical compositions, comprising a, subject compound. The embodiments provide compounds of the general Formula (II), as well as compositions, including pharmaceutical compositions, comprising a su ...


4
Beigelman Leonid, Seiwert Scott D, Blatt Lawrence M, Andrews Steven, Haas Julia: Compounds and methods for inhibiting hepatitis c viral replication. Intermune, Array Biopharma, Beigelman Leonid, Seiwert Scott D, Blatt Lawrence M, Andrews Steven, Haas Julia, MALLON Joseph J, April 19, 2007: WO/2007/044893 (56 worldwide citation)

Macrocyclic compounds having the structures described herein arc useful for inhibiting replication of the hepatitis C virus (HCV). In preferred embodiments, the compounds are active against both the NS3 protease and the NS3 helicase of HCV. Formulae (I), (II), (III), (IV) and (V).


5
Blatt Lawrence M, Pan Lin, Seiwert Scott, Andrews Steven W, Martin Pierre, Schumacher Andreas, Beigelman Leonid, Liu Jyanwei, Condroski Kevin, Jiang Yutong, Kaus Robert, Kennedy April, Kercher Timothy, Lyon Michael, Wang bin: Novel macrocyclic inhibitors of hepatitis c virus replication. Intermune, Array Biopharma, Blatt Lawrence M, Pan Lin, Seiwert Scott, Andrews Steven W, Martin Pierre, Schumacher Andreas, Beigelman Leonid, Liu Jyanwei, Condroski Kevin, Jiang Yutong, Kaus Robert, Kennedy April, Kercher Timothy, Lyon Michael, Wang bin, MALLON Joseph J, November 13, 2008: WO/2008/137779 (56 worldwide citation)

The embodiments provide macrocyclic compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treatin ...


6
Blatt Lawrence M: Methods for treating hcv infection. Intermune, Blatt Lawrence M, BORDEN Paula A, February 16, 2006: WO/2006/016930 (49 worldwide citation)

The present invention provides methods of treating hepatitis C virus (HCV) infection; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in ...


7

8
Blatt Lawrence M, Seiwert Scott D, Ozes Osman N: Combination therapy for proliferative disorders. Intermune, Blatt Lawrence M, Seiwert Scott D, Ozes Osman N, BORDEN Paula A, December 9, 2004: WO/2004/105684 (16 worldwide citation)

The present invention provides methods of treating proliferative disorders, including angiogenesis-mediated disorders, cancer, and fibrotic disorders. In some embodiments, the methods involve administering a Type II interferon receptor agonist and a Type I interferon receptor agonist. In other embod ...


9
Ozes Osman N, Blatt Lawrence M, Seiwert Scott D: Use of pirfenidone in therapeutic regimens. Intermune, Ozes Osman N, Blatt Lawrence M, Seiwert Scott D, BORDEN Paula A, May 6, 2005: WO/2005/040758 (14 worldwide citation)

The present invention provides methods for treating a disorder, and methods for inhibiting a stress-activated protein kinase (SAPK) in a cell in an individual, the methods generally involving administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog; c ...


10
Blatt Lawrence M, Seiwert Scott D, Beigelman Leonid, Radhakrishnan Ramachandran: Pyridone derivatives for modulating stress-activated protein kinase system. Intermune, Blatt Lawrence M, Seiwert Scott D, Beigelman Leonid, Radhakrishnan Ramachandran, RIN LAURES Lily, November 16, 2006: WO/2006/122154 (12 worldwide citation)

Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentag ...